ClinicalTrials.gg
Not yet recruitingNCT07942285Updated Nov 17, 2026

Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5

A Phase 3 interventional study of sintilimab+IBI310+chemotherapy and sintilimab+chemotherapy in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.

Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.

02

Conditions studied

  • Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 251 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years.
  2. confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy.
  3. -negative status.
  4. At least one measurable or evaluable lesion per v1.1.
  5. CPS \<5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory.
  6. PS 0-1
  7. ≥3 months.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment.
  2. Active tumor bleeding.
  3. Severe gastrointestinal obstruction or difficulty swallowing tablets.
  4. Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions.
  5. Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity.
  6. Grade ≥3 to monoclonal antibodies or chemotherapy components.
  7. History of seizures, , spinal cord compression, or meningeal .
  8. cardiovascular or cerebrovascular disease.
  9. History of severe toxicity requiring permanent discontinuation of or study-related treatment.
  10. History of noninfectious enteritis requiring within 1 year before treatment.
  11. Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension.
  12. Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
525 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Sintilimab Plus Ipilimumab N01 and Chemotherapy

    Drug: sintilimab+IBI310+chemotherapy

  • Active comparator
    Active Comparator

    Sintilimab Plus Chemotherapy

    Drug: sintilimab+chemotherapy

Interventions

  • Drugsintilimab+IBI310+chemotherapy

    Drug pages: Sintilimab · Anti-CTLA-4 Monoclonal Antibody IBI310

    Patients in the experimental arm will receive a single dose of ipilimumab N01 (3 mg/kg IV), combined with sintilimab (200 mg IV, Q3W) and XELOX or SOX chemotherapy for 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. Subsequent dosing of ipilimumab N01 will be determined based on radiological assessments per RECIST v1.1 and safety evaluations.

  • Drugsintilimab+chemotherapy

    Patients in the active comparator arm will receive sintilimab (200 mg IV, Q3W) plus XELOX or SOX chemotherapy for up to 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the time from randomization to death from any cause

    Time frame: From randomization to death from any cause, assessed up to 48 months.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first disease progression per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: From baseline to disease progression, assessed up to 24 months.

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of response-evaluable participants with measurable disease at baseline who achieve a best overall response of confirmed complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.

  3. Incidence of Adverse Events (AEs)

    Percentage of participants experiencing AEs, including severity and relationship to study treatment.

    Time frame: From the first dose through the protocol-defined safety follow-up period, up to 48 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942285
Responsible party
Jia Wei (MD, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Anti-CTLA-4 Monoclonal Antibody IBI310

Start the discussion